The Potential Therapeutic Role of Beta-Caryophyllene as a Chemosensitizer and an Inhibitor of Angiogenesis in Cancer DOI Creative Commons
Emad A. Ahmed

Molecules, Journal Year: 2025, Volume and Issue: 30(8), P. 1751 - 1751

Published: April 14, 2025

The natural, highly lipophilic bicyclic sesquiterpenes, Beta-Caryophyllene (BCP), was highlighted in several recent preclinical studies to enhance chemo-sensitization chemo-resistant tumors and efficiently inhibit angiogenesis cancer cells’ ability invade metastasize. Previous have researched the reasons for synergistic effect of combination therapy its role as a chemosensitizer an inhibitor through investigating involved mechanisms signaling molecules. These include nature BCP, selective interaction BCP with CB2, binding affinity receptor sites at angiogenic vascular endothelial growth factor, upstream on JAK1/STAT3 pathway other pathways. Herein, enhancing inhibiting metastasize are highlighted. appears be promising candidate treating when co-supplemented drugs such cisplatin, gemcitabine sorafenib. Clinical trials needed validate potential therapeutic co-supplementary drug therapy, helping sensitize response drugs, modulating pathways, lowering drugs’ doses besides working anti-angiogenetic drug.

Language: Английский

Immunomodulatory Potential of Kaempferol Isolated from Peronema canescens Jack. Leaves Through Inhibition of IL-6 Expression DOI Open Access
Muhammad Ryan Radix Rahardhian, Sri Adi Sumiwi, Yasmiwar Susilawati

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(7), P. 3068 - 3068

Published: March 27, 2025

Sungkai leaves were selected due to their herbal medicine prevalence and documented biological activities. This study explores the immunomodulatory potential of kaempferol isolated from (Peronema canescens Jack.) through a combination in silico vitro methods. P. extracted with ethanol using maceration, followed by fractionation n-hexane, ethyl acetate, water separatory funnel. Among all fractions, acetate fraction demonstrated strongest inhibitory effect on IL-6 (Interleukin 6) expression, leading further separation for enhanced analysis its activity. The resulting sub-fractions purified vacuum liquid chromatography n-hexane gradient. Sub-fraction E was preparative thin-layer obtain pure compound identified as UV, FTIR, MS, NMR analyses. then evaluated molecular docking dynamics simulations, employing MM-PBSA (Molecular Mechanics Poisson-Boltzmann Surface Area) binding affinity calculations. Kaempferol showed (ΔG) -5.98 kcal/mol, slightly stronger than TLA (tartaric acid) (-5.90 kcal/mol). Key interactions amino acid residues, such Gln175, Arg182, Arg179, observed. Additionally, simulation that exhibited better stability between 15 ns 100 ns. has strong van der Waals (-17.02 kcal/mol) electrostatic (-293.16 kcal/mol), free energy (-17.85 significantly (-1.00 stability, combined ability reduce expression vitro, highlights kaempferol's potential.

Language: Английский

Citations

0

The Potential Therapeutic Role of Beta-Caryophyllene as a Chemosensitizer and an Inhibitor of Angiogenesis in Cancer DOI Creative Commons
Emad A. Ahmed

Molecules, Journal Year: 2025, Volume and Issue: 30(8), P. 1751 - 1751

Published: April 14, 2025

The natural, highly lipophilic bicyclic sesquiterpenes, Beta-Caryophyllene (BCP), was highlighted in several recent preclinical studies to enhance chemo-sensitization chemo-resistant tumors and efficiently inhibit angiogenesis cancer cells’ ability invade metastasize. Previous have researched the reasons for synergistic effect of combination therapy its role as a chemosensitizer an inhibitor through investigating involved mechanisms signaling molecules. These include nature BCP, selective interaction BCP with CB2, binding affinity receptor sites at angiogenic vascular endothelial growth factor, upstream on JAK1/STAT3 pathway other pathways. Herein, enhancing inhibiting metastasize are highlighted. appears be promising candidate treating when co-supplemented drugs such cisplatin, gemcitabine sorafenib. Clinical trials needed validate potential therapeutic co-supplementary drug therapy, helping sensitize response drugs, modulating pathways, lowering drugs’ doses besides working anti-angiogenetic drug.

Language: Английский

Citations

0